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Background: Primary hepatic sarcoma (PHS) is a rare primary liver malignancy. The histological types of PHS are
diverse, and the clinical outcomes and management mainly depend on the histopathology. This study aims to
evaluate the results of surgical intervention.
Methods: Between January 2003 and June 2009, 13 adult patients with pathologically proven PHS were identified
by record review. The patients’ demographic profile, tumor characteristics, treatment modalities, and outcomes
were reviewed and analyzed. The end of follow-up was December 2014.
Results: Nine (69%) underwent curative liver resection and two underwent liver transplantation; the others received
non-operative treatments. The pathologic findings were six (46%) angiosarcomas, four (30.7%) undifferentiated
sarcomas, one (7.6%) leiomyosarcoma, one (7.6%) malignant mesenchymoma, and one (7.6%) hepatic epithelioid
hemangioendothelioma. The median follow-up was 31.4 (2.8 ~ 142.5) months. The 1-, 2-, and 5-year survival of
surgical patients were 72.7%, 63.6%, and 36.4%, respectively. Importantly, the 1-, 2-, and 5-year survival rates of
non-angiosarcoma patients were superior to those of angiosarcoma (85.7% vs. 33.3%, 71.4% vs. 16.7%, and 57.1% vs.
0%, respectively, P = 0.023).
Conclusions: Surgical intervention provides the possibility of long-term survival from PHS. Angiosarcoma is
associated with a more dismal outcome than non-angiosarcoma.
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Primary hepatic sarcoma (PHS) is a rare malignancy ac-
counting for less than 1% of all liver malignancies [1-3].
The etiologies of this disease are still not well-known,
unlike hepatocellular carcinoma (HCC) which is the
most common histology of primary hepatic malignancy
and closely associated with infection of viral hepatitis, al-
coholism, and liver cirrhosis. The clinical presentations
of PHS are usually non-specific such as abdominal pain
and weight loss [4,5]. HCC and cholangiocarcinoma are
associated with the elevation of alpha-fetoprotein (AFP)
and carbohydrate antigen 19-9 (CA 19-9), respectively.
But no tumor marker has been identified to accurately
detect PHS. The treatment guidelines of HCC evolved
and have been very well-established in recent decades* Correspondence: ufel4996@gmail.com
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unless otherwise stated.[4]. In contrast, PHS is less studied and no clinical
guideline can be applied.
PHS has a wide diversity of histological types. Leio-
myosarcoma and angiosarcoma are the most common
histological types [1,6-9]. Undifferentiated sarcoma most
often occurs in childhood but is also common in adults.
The histological nomenclature for undifferentiated sar-
coma was not uniform before 1978. The names were
mesenchymoma, primary sarcoma of liver, fibromyxosar-
coma, and malignant mesenchymoma.
The clinical outcomes and treatment are quite differ-
ent in each type of histology. Radiotherapy is commonly
used for extremity sarcoma, but its detrimental adverse
effects when delivered at high doses to abdominal organs
limit its application when treating hepatic sarcoma [1].
Without surgery, chemotherapy provides minimal ben-
efits of survival in sarcomas. In the past two decades,
substantial improvement in surgical technique, periopera-
tive management, and earlier diagnosis have resulted ins is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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rates for patients undergoing hepatectomy and liver
transplantation (LT) [10-13]. Aggressive surgical ap-
proach seems to be the only effective treatment to
achieve possible long-term survival for PHS [7].
Since PHS is rare, the course of disease, prognostic
factors, and consensus on management are not well-
clarified. The aim of this study is to analyze our surgical
experience in the management of this rare malignancy.
Methods
We retrospectively reviewed the records of 13 adult pa-
tients with PHS confirmed by pathology at Kaohsiung
Chang Gung Memorial Hospital from January 2003 to
June 2009. Patients were followed up till December 2014.
This study was approved by the Institutional Review
Board of this hospital. Written informed consent was ob-
tained from the patient for the publication of this report
and any accompanying images.
The diagnostic imaging modalities were abdominal
ultrasound, computed tomography (CT), or magnetic
resonance imaging (MRI) with or without hepatic angi-
ography. Laboratory blood tests included hepatitis B
antigen and antibody, hepatitis C antibody, serum AFP,
carcinoembryonic antigen (CEA), CA 19-9, serum albu-
min, serum total bilirubin, aspartate aminotransferase, ala-
nine aminotransferase, differentiated blood cell counts,
international normalized ratio, and prothrombin time.
Patients who underwent work-up for possible LT under-
went other examinations that included panendoscopy,
colonoscopy, chest and brain images, and bone scan to
screen out possible distant metastases or double can-
cers. Patients who were identified as candidates for hep-
atic resection underwent indocyanine green clearance
test [10,11]. Resectability was determined by tumor ex-
tent, possible residual liver volume on imaging, and bio-
chemical tests especially indocyanine green clearance
test [14]. Patients with resectable liver tumors and had
resectable solitary lung metastasis were also considered
as resection candidates.
The surgery types were hepatectomy (anatomical and
non-anatomical) and LT (brain-death deceased donor
and living-related donor). The procedures followed stan-
dardized surgical protocols and techniques and were de-
scribed elsewhere in detail [15-17]. The resection margin
was defined as follows: R0: no residual tumor; R1: micro-
scopic residual tumor; and R2: macroscopic residual
tumor [18].
The patients were followed in the out-patient clinic at
1 month after the operative procedure and every
3 months thereafter with regular abdominal ultrasound,
liver function test, and tumor markers. If there was a
suspicious recurrence, computed tomography scan or
magnetic resonance imaging was performed.For patients with unresectable or recurrent disease,
transarterial embolization, radio frequency ablation (RFA),
percutaneous ethanol injection (PEI), chemotherapy, or
combined treatments were applied.
The descriptive statistics were presented with median
(range). The overall survival, disease-free survival, and
survival between different histological types were deter-
mined by the Kaplan-Meier method and compared by
the log-rank test. A P value <0.05 was considered sig-
nificant. Statistical evaluation was performed using the
Statistical Package for Social Sciences 18 for Windows
(SPSS Inc., Chicago, IL).
Results
There were eight male and five female (ratio: 1.6:1) pa-
tients. The median age was 48 (21 to 70) years. The
demographics were listed in Table 1. Most patients
(69%) presented with abdominal pain mainly in the
right upper quadrant or periumbilical areas. Seven
(53%) patients presented with anemia and two (15%)
were with thrombocytopenia. The AFP, CEA, and CA
19-9 were within the normal reference range values except
in one patient with angiosarcoma who had CA 19-9 of
337.92 U/ml.
Seven (53%) patients had pretreatment biopsy where
six had proven malignancies and one was negative of
malignancy. The positive and accurate rates of percutan-
eous biopsy were 85.7% and 57.1%, respectively. No com-
plications or needle-tract tumor seeding were associated
with percutaneous biopsy in this series.
Three patients had hepatitis B virus infection. One had
hepatitis B and C co-infection. But no patient with
angiosarcoma had viral hepatitis. All liver function tests
were within normal limits except in patient 12 with
hepatitis B and C co-infection where the bilirubin was
6 mg/dl.
The pathology reports showed that angiosarcoma (n = 6,
46%) was the most common histological type in our series.
Other histological types included four (30.7%) undifferen-
tiated sarcomas, one (7.6%) each for hepatic epithelioid
hemangioendothelioma (HEHE), leiomyosarcoma, and
malignant mesechymoma. Patient 8 who had leiomyo-
sarcoma over segment 1 of the liver also had HCC in
the right lobe simultaneously.
Eleven patients (84.6%) underwent surgical treatment.
Among them, nine patients underwent liver resection
and two underwent LT. The treatment course of each
patient is described as below and is summarized in
Table 1.
Patient 1 who had angiosarcoma underwent right lob-
ectomy for a 14-cm tumor with diaphragm invasion.
After 26.3 months, he had peritoneal recurrence with
surgical proof. We arranged 5 cycles of systemic chemo-
therapy with doxorubicin, mesna, dacarbazine (DTIC),
Table 1 The demographics, histology, surgical procedures, and survival of the patients
Sex Age Preoperative biopsy Pathology Size (cm) Operation Recurrence (months) Follow-up (months)
1 M 46 Angiosarcoma 14 Right lobectomy 26.3 E 44.2
2 M 54 Angiosarcoma Angiosarcoma 10 Right lobectomy 4.78 E 9.1
3 M 70 Angiosarcoma 2.5 Left lobectomy + PEI to S8 2.34 E 3.5
4 M 68 Sarcoma Angiosarcoma 16 Right lobectomy 22.89 E 31.4
5 F 60 Angiosarcoma Angiosarcoma 2.5 Nil E 8.7
6 M 46 Angiosarcoma Angiosarcoma 14 Nil E 2.7
7 F 27 Embryonal sarcoma 14 Right lobectomyb A 142.5
8 M 39 Leiomyosarcoma 0.6 Right + partial S1-2a 1.0 E 33.7
9 F 39 Neuroendocrine
tumor
HEHE 2.7 Deceased donor LTa A 135.9
10 F 21 Undifferentiated sarcoma 5 S4 resection + resection of
solitary lung metastasisb
A 123.7
11 M 69 Malignant spindle
cell neoplasm
Undifferentiated sarcoma 15.5 Left lobectomyb 3.7 E 8.2
12 M 49 Negative Malignant
mesenchymoma
4.5 Living donor LT 5.6 E 19.4
13 F 61 Undifferentiated sarcoma 16 Right lobectomy A 65.4
HEHE hepatic epithelioid hemangioendothelioma, PEI percutaneous ethanol injection, LT liver transplantation, A alive, E expired, S8 segment 8 of liver, S1-2 segment 1
and 2 of liver, S4 segment 4 of liver.
aPreoperative TAE; badjuvant chemotherapy.
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died because of tumor progression and liver failure.
Patient 2 had a right lobectomy for a 10-cm angiosar-
coma and had multiple intrahepatic recurrence 4.8 months
after resection. There was no palliative treatment.
Patient 3 had a left lobectomy for a 2.5-cm angiosar-
coma and intraoperative PEI for a segment 8 liver tumor.
He had an intrahepatic recurrence 2.3 months after resec-
tion. He received transarterial embolization (TAE) once.
Fatal recurrent tumor rupture occurred 3.5 months after
resection.
Patient 4 had a right lobectomy for a 16-cm angiosar-
coma. Intra-abdominal and pulmonary metastasis hap-
pened 22.9 months after liver resection. The patient
expired under supportive treatment.
Patient 5 was diagnosed with hepatic angiosarcoma
with needle biopsy. She received multiple sessions of
chemotherapy with adriamycin in combination with tax-
otere or ifosfamide. Tumor progression with rupture oc-
curred 6 months after diagnosis and TAE was applied.
She expired 8.7 months after diagnosis due to a large
middle cerebral artery territory infarction.
Patient 6 was diagnosed with hepatic angiosarcoma
with needle biopsy. He died 2.7 months after biopsy
without further treatment.
Patient 8 who had leiomyosarcoma and HCC had TAE
for huge right lobe HCC before operation. He had right
lobectomy and wedge resection of segment 1 liver
tumor. Recurrence occurred 1 month after resection.
There were multiple sessions of TAE for recurrence.Because of poor control of recurrent tumors, we ar-
ranged two courses of chemotherapy with mitoxantrone,
cisplatin, and 5-Fu. The tumor still progressed. This pa-
tient expired 33.7 months after resection.
Patient 9 who was diagnosed with neuroendocrine
tumor received 6 cycles of chemotherapy with 5-Fu and
leucovorin and five sessions of TAE in another hospital.
She received cadaveric LT afterwards. There was no ad-
juvant therapy.
Patient 10 had segment 4 liver resection and combined
wedge resection of undifferentiated sarcoma with soli-
tary lung metastasis. She received 6 cycles of chemother-
apy with ifosfamide, doxorubicin, dacarbazine, and
mesna. The recurrence-free survival was 123.7 month at
the end of this study.
Patient 11 had a left lobectomy for undifferentiated
sarcoma. The pathology showed portal vein micro- and
macro-vascular invasion, left hepatic vein invasion, and
bile duct invasion. He received 4 cycles of chemotherapy
with doxorubicin, mesna and ifosfamide, and also TAE.
He died because of disease progression.
Patient 12 underwent living-related donor LT for cir-
rhosis and clinically diagnosed HCC. The final path-
ology was malignant mesenchymoma of the liver.
Intrahepatic recurrence occurred 5.6 months after LT.
We arranged multiple sessions of RFA and PEI. But the
tumor recurred and progressed. He expired 19.4 months
after LT.
Patient 13 had a right lobectomy for a 16-cm undiffer-
entiated sarcoma. There was no adjuvant therapy. He
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time: 65.4 months).
Seven patients had disease recurrence. The time of re-
currence was 4.8 (1.0 ~ 26.3) months. All (4/4, 100%)
angiosarcoma patients had recurrence after surgery with
time to recurrence of 13.8 (2.4 ~ 26.3) months. Two
(40%) patients in the undifferentiated sarcoma group
had recurrence with the time of 3.7 and 5.6 months.
The resection margin status was R0 in nine patients
and R1 in two patients. The 2-year survival rate of pa-
tients with R0 resection was 77.8%, but two patients
with R1 resection died within 1 year (P = 0.006).
No patient lost follow-up. The median survival was
31.4 (2.7 ~ 142.5) months at the end of study. The over-
all 1-, 2-, and 5-year survival rates were 61.5%, 53.8%,
and 30.8%, respectively. The 1-, 2-, and 5-year survival
rates of surgical patients were 72.7%, 63.6%, and 36.4%,
respectively. All patients with angiosarcoma expired dur-
ing study time with median survival of 8.9 (2.7 ~ 44.2)
months. The patients with non-angiosarcoma PHS were
with median survival of 65.4 (8.2 ~ 142.5) months. The
1-, 2-, and 5-year survival rates of the angiosarcoma
group were 33.3%, 16.7%, and 0%, respectively. The 1-,
2-, and 5-year survival rates of the non-angiosarcoma
group were 85.7%, 71.4%, and 57.1%, respectively. The
1-, 2-, and 5-year survival rates of the undifferentiated
sarcoma group (including undifferentiated sarcoma, em-
bryonal sarcoma, and malignant mesenchymoma) were
80%, 60%, and 60%, respectively. The survival of non-
angiosarcoma patients was significantly superior to those
of angiosarcoma (P = 0.023) (Figure 1).Figure 1 The survival of the angiosarcoma group is significantly
worse than the non-angiosarcoma group (P = 0.023).Discussion
Since PHS is a relatively rare malignancy, only few series
and case reports have been discussed about the manage-
ment and outcome of PHS in the literature. In this
study, the clinical presentations of our patients were
non-specific such as abdominal pain and weight loss
which were similar with other series [4,5]. Several risk
factors are theorized to cause PHS but the pathogenesis
still remains unclear. The recognized risk factors of
angiosarcoma are exposure to thorotrast, arsenic, and
vinyl chloride monomer [4]. After reviewing our pa-
tients’ personal and occupational history, no patient had
contact with these materials. Unlike HCC which is
highly associated with viral and alcoholic hepatitis, we
found only 4 (30.7%) of the 13 patients were with viral
hepatitis. Furthermore, in the angiosarcoma group, there
were no patients with underlying viral hepatitis. This
finding was similar to published results [19]. Besides, no
specific serologic marker (such as CEA, AFP, and CA
19-9) is specific to sarcoma [6]. Hence, early detection
for PHS proves to be difficult. Due to the absence of
specific markers and symptoms, the reported median
delay of diagnosis was 4 months and there was a 6-month
delay of treatment [7]. Owing to delayed diagnosis, <20%
of patients have the chance to receive radical oper-
ation [20,21].
Regarding image studies, the most favorable modalities
are multiphase CT and MRI. Some of the PHSs have
characteristic features but they still frequently overlap
with other lesions [22]. The imaging presentation is
heterogeneous within each kind of PHS or between dif-
ferent kinds of PHS [22,23]. Angiosarcoma might be
multiple nodules, solitary huge mass, or diffusely infil-
trating lesion. Of them, 17% to 27% have a chance of
intraperitoneal or intratumoral hemorrhage [22-25].
Most angiosarcomas are hypoattenuating compared
with normal liver. Focal areas of enhancement with bi-
zarre shapes and central enhancement or peripheral
ring-shaped enhancement is considered to be different
from cavernous hemangioma. In MRI, angiosarcoma
may contain areas of high-signal intensity on T1-
weighted images and heterogeneous architecture on
T2-weighted images [26,27]. HEHE are mostly multiple
(82%). Enhanced CT usually shows marginal enhance-
ment in the arterial phase and isodense to liver paren-
chymal in late phase. And there might be a halo or
target sign in larger tumors [28,29]. Leiomyosarcoma
in CT have been described as a large, well-defined,
heterogeneous-hypodensity mass with internal and per-
ipheral enhancement. And it can be a large hypervascu-
lar mass with hemorrhage or liquescent necrosis [30].
Undifferentiated sarcoma is usually a large, solitary and
well-circumscribed mass with areas of hemorrhage, ne-
crosis, and cystic degeneration. Tumor enhancement is
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of undifferentiated sarcomas are a discordant cystic
mass due to high-water content which are hypointense
on T1-weighted images and have high-signal intensity
on T2-weighted images. It is usually with heteroge-
neous enhancement in contrast study and might be
more prominent on delayed-phase images [31,32]. In-
deed, these PHSs have characteristic features in im-
aging studies, but it is still difficult to differentiate
when available information is limited. Histopathology
is essential for diagnosis.
The definite diagnosis of PHS should be made with
tissue proof. For resectable tumor, preoperative biopsy
might not be necessary. But histopathological confirm-
ation of unresectable tumor may serve as the guide for
therapies other than resection such as chemotherapy,
loco-regional therapy, or even for LT. Seven (54%) pa-
tients had pretreatment percutaneous biopsy in our
series. Of the pretreatment biopsies, 86% were positive
for malignancy. And 57% of them were consistent with
final pathology. The diagnostic rates of biopsy were
similar with the results of other studies [23]. The biopsy
result might not give us the accurate diagnosis. But it
would help us to exclude the diagnosis of HCC. Some
treatments such as LT are indicated for cirrhosis and
HCC within certain criteria in order to achieve a good
outcome. Our patient 12 had no tissue proof before LT
and underwent LT under clinically diagnosed HCC. But
explant pathology showed malignant mesenchymoma.
Recurrence came early and was progressive. Definite
diagnosis with tissue proof is crucial for medical treat-
ment and transplant candidates.
As most literatures’ conclusion, complete surgical re-
section is the treatment of choice and provides the only
possibility of long-term survival [6,7,9]. Patients with
PHS did not survive more than 1 year without operation
in our series. Surgical treatment showed potential benefit
especially in non-angiosarcoma PHS patients; the 5-year
survival rate was 57.1%. For different histological types,
leiomyosarcomas are reported with poor outcome [33].
In our patient 8, he had early recurrence 1 month after
resection, because the pathology showed HCC and leio-
myosarcoma in different parts of the liver and we did
not have tissue diagnosis after recurrence. The true hist-
ology of recurrence was not known. In previous litera-
ture, the prognosis of undifferentiated sarcoma was
poor, but recent evidence shows that long-term survival
is possible after radical resection with or without adju-
vant chemotherapy [34]. The 5-year survival of patients
with undifferentiated sarcoma was 60% in our series.
And these three survivors had the follow-up time from
65.4 months to 142.5 months. Initially, our patient 10
were presented with segment 4 liver tumor and solitary
lung metastasis. We arranged liver resection combinedwith thoracoscopic wedge resection followed by adjuvant
chemotherapy. The patient survives more than 10 years
without recurrence. Aggressive surgical approach should
be considered seriously and might be reasonable for undif-
ferentiated sarcoma. The vascular malignancies in PHS
are HEHE and angiosarcoma. The outcome of our patient
with HEHE was excellent after LT. Till the end of our
study, the recurrence-free survival was 135.9 months. In
contrast, the outcome of angiosarcoma was dismal. Even
after potentially curative resection, none of the angiosar-
coma patients survived more than 5 years and the 2-year
survival rate was 16.7% only. In brief, angiosarcoma had a
significantly worse outcome than non-angiosarcoma
which was consistent with reports in related literature [6],
and one of the important factors affecting survival was the
histological type.
The radicality or extent of the operative procedure
also affects the outcome significantly (P = 0.006). In R0
patients, 77.8% survived more than 2 years. But in pa-
tients with R1, all died within 1 year. The 5-year sur-
vival in our series (30.8%) is relative lower than in
other series (37% ~ 65.2%) [1,6,7]. We believed that
one of the reasons was that more patients were diag-
nosed with angiosarcoma in this study (46%) than in
other series (16.7% ~ 22.7%).
The indication of PHS undergoing LT depends on the
type of histopathology. Due to early recurrence and poor
outcome, angiosarcoma is considered as an absolute
contraindication [35]. The most favorable type of PHS
for LT is HEHE. Gores et al. reported that the 1-, 5-,
and 10-year patient survival rates from HEHE after LT
were 93%, 83%, and 72%, respectively [36], which are
similar or even better than the results of LT for other
diseases. Our patient 9 with HEHE underwent LT and is
currently alive without recurrence to date for more than
11 years. In contrast, our patient 12 who had malignant
mesenchymoma underwent LT and early recurrence oc-
curred. Despite multiple sessions of locoregional therapy,
he expired 19.4 months after LT. Regarding histological
types other than HEHE, the indication for LT is still
controversial [35].Conclusions
In conclusion, despite the limited number of patients in
this series, we found that angiosarcoma is associated
with a much worse outcome than other types. We pro-
posed that PHS could be separated into ‘angiosarcoma’
and ‘non-angiosarcoma.’ Radical surgical resection offers
the only opportunity to achieve long-term survival. Early
diagnosis is critical to increase the possibility of resec-
tion, but it is difficult to make an early detection. Unre-
sectable HEHE is an indication for LT where long-term
survival may be expected.
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